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fewer than 6 months. CONCLUSIONS: These results
support the common belief that physicians differentially
prescribe SSRIs according to comorbid symptoms. Ob-
served differences in the prevalence of diagnoses across
SSRI therapies are consistent with differences in the range
of approved indications across drugs and preferential
prescribing of paroxetine for patients with comorbid
anxiety disorders.
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OBJECTIVE: To examine pre-treatment differences in
characteristics of patients with schizophrenia treated
with olanzapine and risperidone, as reported in epidemi-
ologic studies. METHOD: All 15 non-randomized stud-
ies with olanzapine and risperidone cited in Medline or
presented at major conferences (APA, ECNP, WPA,
ISPOR) through 1999 were included. The direction, mag-
nitude, and statistical significance from all comparisons
of pre-treatment characteristics for schizophrenia pa-
tients initiating therapy on olanzapine or risperidone are
summarized. RESULTS: Several studies found olanzapine
patients were more likely to be younger and male. One of
six studies found younger mean age at onset, though
prior duration of illness results had no consistent direc-
tion. Other specific comparisons were included in only
one or two studies. History of hospital admission results
were mixed, though olanzapine patients had significantly
higher prior hospitalization costs in the one study with
that measure. Patients initiated on olanzapine were more
likely to have prior use of clozapine, depot antipsychot-
ics, and/or antidepressants, whereas patients initiated on
risperidone were more likely to have anticholinergic use
at therapy start. In one study, patients initiated on olan-
zapine had mean CGI scores and/or GAF scores indica-
tive of greater severity. CONCLUSIONS: When evalu-
ated, significant pre-treatment patient differences were
often found. Physicians may be choosing olanzapine ther-
apy for more complicated schizophrenic patients, indi-
cated by prior hospitalization cost, medication use, and
clinical assessment scores.
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OBJECTIVE: To determine how deficit syndrome relates
to patterns of antipsychotic drug use among persons with
schizophrenia receiving community-based care. METH-
ODS: Study participants were enrolled in the US Schizo-
phrenia Care and Assessment Program (SCAP). Data
were obtained from participants who completed the base-
line and 6-month assessments and were using antipsy-
chotic medications at baseline (n  1019). Presence of
deficit syndrome was assigned based on proxy methods
using clinical data (Kirkpatrick B., et al., 1989). Antipsy-
chotics were categorized as first-generation, second-gen-
eration, or other. Few participants received antipsychot-
ics in the ‘other’ category (2%) and were not included in
these analyses. Baseline characteristics and the presence
of deficit syndrome were used to predict two outcomes:
(1) the likelihood of receiving first-generation antipsy-
chotics at the initial assessment, and (2) the likelihood of
switching from one antipsychotic class to another be-
tween assessments. Covariates included demographic
(gender, race, age, marital status, education, insurance),
clinical (GAF, hallucinations/delusions, disorganization),
medication adherence, and site variables. Logistic regres-
sion was applied. RESULTS: Deficit syndrome was not
significantly related to use of a 1st-generation agent at
baseline. A positive association was found for African
Americans (.0004), lower hallucination/delusion scores
(.02), and several site indicators (.05) ( Orlando, Den-
ver, Baltimore, and San Diego). The probability of
switching antipsychotic classes between assessments was
significantly related to one site indicator (.01) (Orlando);
weak evidence (.08) of lower GAF scores being associ-
ated with a switch was observed. The presence of deficit
syndrome did not achieve significance in either model.
CONCLUSIONS: The deficit syndrome has been studied
extensively in its relation to neurological function and
course of illness. In the SCAP population of patients re-
ceiving community-based care at diverse settings, we do
not find a relation between deficit syndrome and two
measures of antipsychotic drug assignment. Further re-
search may include evaluation of the relationship be-
tween deficit syndrome and drug assignment patterns
over time.
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OBJECTIVES: The purpose of this study was to assess
the one-year direct schizophrenia-related treatment costs,
mental health care costs and total health care costs for
patients diagnosed with schizophrenia and initiating ther-
apy with either olanzapine or risperidone. METHODS: A
retrospective analysis of the integrated medical and phar-
macy claims of a large, geographically diverse, commer-
cially insured population was conducted. A previously
validated algorithm to identify schizophrenics was used
for patient selection. The confirmed schizophrenia pa-
